Bellde­grun and Chang groom their biotech uni­corn Al­lo­gene for a mon­ster $288M — or so — IPO

Arie Bellde­grun and David Chang are think­ing big again, of course.

To­day the pair run­ning the biotech start­up Al­lo­gene, a CAR-T com­pa­ny $AL­LO look­ing to make his­to­ry pi­o­neer­ing off-the-shelf cell ther­a­peu­tics, out­lined plans to sell 16 mil­lion shares in the com­pa­ny at $16 to $18 a share. That’s $288 mil­lion at the top of the range — though these 2 may not be sat­is­fied with any­thing less than more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.